Biogen PE Ratio 2010-2022 | BIIB
Current and historical p/e ratio for Biogen (BIIB) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Biogen PE ratio as of May 23, 2022 is 11.44.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Biogen PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2022-05-23 |
199.40 |
|
20.41 |
| 2022-03-31 |
210.60 |
$9.77 |
21.56 |
| 2021-12-31 |
239.92 |
$10.40 |
23.07 |
| 2021-09-30 |
282.99 |
$10.22 |
27.69 |
| 2021-06-30 |
346.27 |
$12.46 |
27.79 |
| 2021-03-31 |
279.75 |
$19.06 |
14.68 |
| 2020-12-31 |
244.86 |
$24.45 |
10.01 |
| 2020-09-30 |
283.68 |
$30.21 |
9.39 |
| 2020-06-30 |
267.55 |
$34.14 |
7.84 |
| 2020-03-31 |
316.38 |
$32.40 |
9.76 |
| 2019-12-31 |
296.73 |
$31.47 |
9.43 |
| 2019-09-30 |
232.82 |
$28.12 |
8.28 |
| 2019-06-30 |
233.87 |
$26.88 |
8.70 |
| 2019-03-31 |
236.38 |
$23.21 |
10.18 |
| 2018-12-31 |
300.92 |
$21.60 |
13.93 |
| 2018-09-30 |
353.31 |
$15.47 |
22.84 |
| 2018-06-30 |
290.24 |
$14.11 |
20.57 |
| 2018-03-31 |
273.82 |
$14.00 |
19.56 |
| 2017-12-31 |
318.57 |
$11.92 |
26.73 |
| 2017-09-30 |
313.12 |
$16.31 |
19.20 |
| 2017-06-30 |
271.36 |
$15.23 |
17.82 |
| 2017-03-31 |
273.42 |
$15.95 |
17.14 |
| 2016-12-31 |
261.39 |
$16.92 |
15.45 |
| 2016-09-30 |
288.53 |
$17.70 |
16.30 |
| 2016-06-30 |
222.89 |
$17.14 |
13.00 |
| 2016-03-31 |
239.95 |
$16.28 |
14.74 |
| 2015-12-31 |
282.37 |
$15.34 |
18.41 |
| 2015-09-30 |
268.35 |
$15.31 |
17.53 |
| 2015-06-30 |
372.33 |
$14.78 |
25.19 |
| 2015-03-31 |
389.19 |
$13.86 |
28.08 |
| 2014-12-31 |
312.88 |
$12.39 |
25.25 |
| 2014-09-30 |
304.92 |
$10.57 |
28.85 |
| 2014-06-30 |
290.63 |
$9.00 |
32.29 |
| 2014-03-31 |
281.93 |
$8.05 |
35.02 |
| 2013-12-31 |
257.69 |
$7.82 |
32.95 |
| 2013-09-30 |
221.92 |
$7.13 |
31.12 |
| 2013-06-30 |
198.36 |
$6.75 |
29.39 |
| 2013-03-31 |
177.54 |
$6.30 |
28.18 |
| 2012-12-31 |
134.91 |
$5.76 |
23.42 |
| 2012-09-30 |
137.53 |
$5.75 |
23.92 |
| 2012-06-30 |
133.08 |
$5.51 |
24.15 |
| 2012-03-31 |
116.14 |
$5.08 |
22.86 |
| 2011-12-31 |
101.44 |
$5.03 |
20.17 |
| 2011-09-30 |
85.86 |
$4.80 |
17.89 |
| 2011-06-30 |
98.55 |
$4.42 |
22.30 |
| 2011-03-31 |
67.72 |
$4.36 |
15.53 |
| 2010-12-31 |
61.80 |
$3.96 |
15.61 |
| 2010-09-30 |
51.73 |
$4.03 |
12.84 |
| 2010-06-30 |
43.74 |
$3.93 |
11.13 |
| 2010-03-31 |
52.90 |
$3.30 |
16.03 |
| 2009-12-31 |
49.31 |
$3.34 |
14.76 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$29.239B |
$10.982B |
|
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
|
